Avadel Pharmaceuticals plc (AVDL) shares surged 10.76% in pre-market trading on Wednesday following the company's release of its first-quarter 2025 financial results and an upward revision of its full-year guidance.

The specialty pharmaceutical company reported a narrower-than-expected loss for Q1, with earnings per share (EPS) of -$0.05, beating analyst estimates. While the company still posted a net loss of $4.92 million, this represents a significant improvement compared to previous quarters. Avadel's net product revenue for the quarter reached $52.511 million, indicating strong sales performance.

Investors were particularly encouraged by Avadel's optimistic outlook for 2025. The company raised its full-year guidance, now expecting to generate between $255 million and $265 million in net product revenue. This upward revision suggests growing confidence in the company's product pipeline and market position. The combination of better-than-expected quarterly results and an improved annual forecast appears to be driving the substantial pre-market rally in Avadel's stock price.